Systemic sclerosis (SSc) or scleroderma is an autoimmune disorder characterized by tissue fibrosis of the skin and internal organs. The etiology of the skin fibrosis is thought to be thickened dermis due to uncontrolled excessive deposition of various extracellular matrix, mainly type I collagen.Systemic treatments with anti-inflammatory and cytotoxic immunosuppressive properties, such as corticosteroids and immunosuppressants, are usually considered for skin sclerosis of patients with SSc. However, their approach must be initiated at the early stage, before the fibrosis is completed, and the effects of the corticosteroids and immunosuppressants are known to be reduced in the late stages of the sclerosis. Furthermore, various significant adverse effects of these treatments must be considered.This paper discusses the present day understanding of therapeutic options using disease-modifying drugs against skin sclerosis of SSc patients and the possible mechanisms. 

1. Korn JH. Immunologic aspects of scleroderma. Curr Opin Rheumatol. 1989;1(4):479-84. PubMed PMID: 2702049.

2. Mauch C, Kreig T. Fibroblast-matrix interactions and their role in the pathogenesis of fibrosis. Rheum Dis Clin North Am. 1990;16(1):93-107. PubMed PMID: 2406813.

3. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202-5. PubMed PMID: 3361530.

4. Steen VD, Medsger TA. Long-term outcomes of scleroderma renal crisis. Ann Intern Med. 2000;133(8):600-3. PubMed PMID: 11033587.

5. Asano Y. Future treatments in systemic sclerosis. J Dermatol. 2010;37(1):54-70. doi: 10.1111/j.1346-8138.2009.00758.x. PubMed PMID: 20175840.

6. Sharada B, Kumar A, Kakker R, Adya CM, Pande I, Uppal SS, et al. Intravenous dexamethasone pulse therapy in diffuse systemic sclerosis. A randomized placebo-controlled study. Rheumatol Int. 1994;14(3):91-4. PubMed PMID: 7839076.

7. Takehara K. Treatment of early diffuse cutaneous systemic sclerosis patients in Japan by low-dose corticosteroids for skin involvement. Clin Exp Rheumatol. 2004;22(3 Suppl 33):S87-9. PubMed PMID: 15344605.

8. Raja J, Denton CP. Cytokines in the immunopathology of systemic sclerosis. Semin Immunopathol. 2015;37(5):543-57. Epub 2015/07/08. doi: 10.1007/s00281-015-0511-7. PubMed PMID: 26152640.

9. Jinnin M. Mechanisms of skin fibrosis in systemic sclerosis. J Dermatol. 2010;37(1):11-25. doi: 10.1111/j.1346-8138.2009.00738.x. PubMed PMID: 20175837.

10. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655-66. doi: 10.1056/NEJMoa055120. PubMed PMID: 16790698.

11. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176(10):1026-34. Epub 2007/08/23. doi: 10.1164/rccm.200702-326OC. PubMed PMID: 17717203; PubMed Central PMCID: PMCPMC2078679.

12. Davas EM, Peppas C, Maragou M, Alvanou E, Hondros D, Dantis PC. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol. 1999;18(6):455-61. PubMed PMID: 10638770.

13. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54(12):3962-70. doi: 10.1002/art.22204. PubMed PMID: 17133610.

14. Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol. 2002;29(11):2371-8. PubMed PMID: 12415594.

15. Balbir-Gurman A, Yigla M, Guralnik L, Hardak E, Solomonov A, Rozin AP, et al. Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience. Isr Med Assoc J. 2015;17(3):150-6. PubMed PMID: 25946765.

16. Filaci G, Cutolo M, Scudeletti M, Castagneto C, Derchi L, Gianrossi R, et al. Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology (Oxford). 1999;38(10):992-6. PubMed PMID: 10534551.

17. van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996;35(4):364-72. PubMed PMID: 8624641.

18. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44(6):1351-8. doi: 10.1002/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I. PubMed PMID: 11407694.

19. Derk CT, Grace E, Shenin M, Naik M, Schulz S, Xiong W. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford). 2009;48(12):1595-9. Epub 2009/10/21. doi: 10.1093/rheumatology/kep295. PubMed PMID: 19846575.

20. Nihtyanova SI, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. Rheumatology (Oxford). 2007;46(3):442-5. Epub 2006/08/09. doi: 10.1093/rheumatology/kel244. PubMed PMID: 16899504.

21. Morton SJ, Powell RJ. Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma. Rheumatology (Oxford). 2000;39(8):865-9. PubMed PMID: 10952740.

22. Nadashkevich O, Davis P, Fritzler M, Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol. 2006;25(2):205-12. Epub 2005/10/14. doi: 10.1007/s10067-005-1157-y. PubMed PMID: 16228107.

23. Matteson EL, Shbeeb MI, McCarthy TG, Calamia KT, Mertz LE, Goronzy JJ. Pilot study of antithymocyte globulin in systemic sclerosis. Arthritis Rheum. 1996;39(7):1132-7. PubMed PMID: 8670321.

24. Stratton RJ, Wilson H, Black CM. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford). 2001;40(1):84-8. PubMed PMID: 11157146.

25. de Clerck LS, Dequeker J, Francx L, Demedts M. D-penicillamine therapy and interstitial lung disease in scleroderma. A long-term followup study. Arthritis Rheum. 1987;30(6):643-50. PubMed PMID: 3606683.

26. Steen VD, Medsger TA, Rodnan GP. D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med. 1982;97(5):652-9. PubMed PMID: 7137731.

27. Jayson MI, Lovell C, Black CM, Wilson RS. Penicillamine therapy in systemic sclerosis. Proc R Soc Med. 1977;70 Suppl 3:82-8. PubMed PMID: 122683; PubMed Central PMCID: PMCPMC1543570.

28. Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum. 1999;42(6):1194-203. doi: 10.1002/1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO;2-7. PubMed PMID: 10366112.

29. Derk CT, Huaman G, Jimenez SA. A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset. Br J Dermatol. 2008;158(5):1063-8. Epub 2008/02/16. doi: 10.1111/j.1365-2133.2008.08452.x. PubMed PMID: 18284395.

30. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci. 2001;27(2):140-6. PubMed PMID: 11532378.

31. Duncan MR, Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol. 1991;97(4):686-92. PubMed PMID: 1940439.

32. Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387(10038):2630-40. Epub 2016/05/05. doi: 10.1016/S0140-6736(16)00232-4. PubMed PMID: 27156934.

33. Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis. 2018;77(2):212-20. Epub 2017/10/24. doi: 10.1136/annrheumdis-2017-211682. PubMed PMID: 29066464; PubMed Central PMCID: PMCPMC5867414.

34. Yoshizaki A. B cell abnormalities and therapeutic strategies in systemic sclerosis. Nihon Rinsho Meneki Gakkai Kaishi. 2016;39(3):197-206. doi: 10.2177/jsci.39.197. PubMed PMID: 27320935.

35. Matsushita T, Hamaguchi Y, Hasegawa M, Takehara K, Fujimoto M. Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity. Rheumatology (Oxford). 2016;55(2):263-7. Epub 2015/09/08. doi: 10.1093/rheumatology/kev331. PubMed PMID: 26350483.

36. Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol. 2006;169(3):954-66. doi: 10.2353/ajpath.2006.060205. PubMed PMID: 16936269; PubMed Central PMCID: PMCPMC1698806.

37. Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009;60(2):578-83. doi: 10.1002/art.24249. PubMed PMID: 19180481; PubMed Central PMCID: PMCPMC2637937.

38. Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74(6):1188-94. doi: 10.1136/annrheumdis-2013-204522. PubMed PMID: 24442885.

39. Ballow M. Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol. 1997;100(2):151-7. PubMed PMID: 9275133.

40. Amital H, Rewald E, Levy Y, Bar-Dayan Y, Manthorpe R, Engervall P, et al. Fibrosis regression induced by intravenous gammaglobulin treatment. Ann Rheum Dis. 2003;62(2):175-7. PubMed PMID: 12525390; PubMed Central PMCID: PMCPMC1754436.

41. Kudo H, Jinnin M, Yamane K, Makino T, Kajihara I, Makino K, et al. Intravenous immunoglobulin treatment recovers the down-regulated levels of Th1 cytokines in the sera and skin of scleroderma patients. J Dermatol Sci. 2013;69(1):77-80. doi: 10.1016/j.jdermsci.2012.09.010. PubMed PMID: 23102713.

42. Blank M, Levy Y, Amital H, Shoenfeld Y, Pines M, Genina O. The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum. 2002;46(6):1689-90. doi: 10.1002/art.10363. PubMed PMID: 12115202.

43. Asano Y, Ihn H, Asashima N, Yazawa N, Mimura Y, Jinnin M, et al. A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion. Rheumatology (Oxford). 2005;44(6):824-6. Epub 2005/03/15. doi: 10.1093/rheumatology/keh600. PubMed PMID: 15769789.

44. Ihn H, Mimura Y, Yazawa N, Jinnin M, Asano Y, Yamane K, et al. High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma. Br J Dermatol. 2007;156(5):1058-60. Epub 2007/03/23. doi: 10.1111/j.1365-2133.2007.07777.x. PubMed PMID: 17381465.

45. Kähäri VM, Heino J, Vuorio T, Vuorio E. Interferon-alpha and interferon-gamma reduce excessive collagen synthesis and procollagen mRNA levels of scleroderma fibroblasts in culture. Biochim Biophys Acta. 1988;968(1):45-50. PubMed PMID: 3122841.

46. Black CM, Silman AJ, Herrick AI, Denton CP, Wilson H, Newman J, et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1999;42(2):299-305. doi: 10.1002/1529-0131(199902)42:2<299::AID-ANR12>3.0.CO;2-R. PubMed PMID: 10025924.

47. Allanore Y, Devos-François G, Caramella C, Boumier P, Jounieaux V, Kahan A. Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis. 2006;65(6):834-5. doi: 10.1136/ard.2005.044453. PubMed PMID: 16699057; PubMed Central PMCID: PMCPMC1798181.

48. Ramos-Casals M, Perez-Alvarez R, Perez-de-Lis M, Xaubet A, Bosch X, Group BS. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med. 2011;124(5):386-94. doi: 10.1016/j.amjmed.2010.11.028. PubMed PMID: 21531225.

49. Avouac J, Allanore Y. Targeted immunotherapies in systemic sclerosis. Clin Exp Rheumatol. 2014;32(2 Suppl 81):165-72. Epub 2014/04/15. PubMed PMID: 24742451.

50. Lam GK, Hummers LK, Woods A, Wigley FM. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol. 2007;34(7):1636-7. PubMed PMID: 17611970.

51. Denton CP, Engelhart M, Tvede N, Wilson H, Khan K, Shiwen X, et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2009;68(9):1433-9. Epub 2008/09/09. doi: 10.1136/ard.2008.096123. PubMed PMID: 18782794.

52. Bosello S, De Santis M, Tolusso B, Zoli A, Ferraccioli G. Tumor necrosis factor-alpha inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis. Ann Intern Med. 2005;143(12):918-20. PubMed PMID: 16365478.

53. Distler JH, Jordan S, Airo P, Alegre-Sancho JJ, Allanore Y, Balbir Gurman A, et al. Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. Clin Exp Rheumatol. 2011;29(2 Suppl 65):S40-5. Epub 2011/05/12. PubMed PMID: 21586217.

54. Asano Y, Bujor AM, Trojanowska M. The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis. J Dermatol Sci. 2010;59(3):153-62. doi: 10.1016/j.jdermsci.2010.06.008. PubMed PMID: 20663647; PubMed Central PMCID: PMCPMC3826615.

55. Noda S, Asano Y, Nishimura S, Taniguchi T, Fujiu K, Manabe I, et al. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. Nat Commun. 2014;5:5797. doi: 10.1038/ncomms6797. PubMed PMID: 25504335; PubMed Central PMCID: PMCPMC4268882.

56. Distler JH, Jüngel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 2007;56(1):311-22. doi: 10.1002/art.22314. PubMed PMID: 17195235.

57. Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 2009;60(1):219-24. doi: 10.1002/art.24186. PubMed PMID: 19116940.

58. Gordon J, Udeh U, Doobay K, Magro C, Wildman H, Davids M, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial. Clin Exp Rheumatol. 2014;32(6 Suppl 86):S-189-93. Epub 2014/08/15. PubMed PMID: 25152211.

59. Prey S, Ezzedine K, Doussau A, Grandoulier AS, Barcat D, Chatelus E, et al. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br J Dermatol. 2012;167(5):1138-44. doi: 10.1111/j.1365-2133.2012.11186.x. PubMed PMID: 23039171.

60. Pope J, McBain D, Petrlich L, Watson S, Vanderhoek L, de Leon F, et al. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum. 2011;63(11):3547-51. doi: 10.1002/art.30549. PubMed PMID: 21769850.

61. Fraticelli P, Gabrielli B, Pomponio G, Valentini G, Bosello S, Riboldi P, et al. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther. 2014;16(4):R144. Epub 2014/07/08. doi: 10.1186/ar4606. PubMed PMID: 25007944; PubMed Central PMCID: PMCPMC4227120.

62. Distler O, Pope J, Denton C, Allanore Y, Matucci-Cerinic M, de Oliveira Pena J, et al. RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. Respir Med. 2017;122 Suppl 1:S14-S7. Epub 2016/09/28. doi: 10.1016/j.rmed.2016.09.011. PubMed PMID: 27746061.

63. Scherer HU, Burmester GR, Riemekasten G. Targeting activated T cells: successful use of anti-CD25 monoclonal antibody basiliximab in a patient with systemic sclerosis. Ann Rheum Dis. 2006;65(9):1245-7. doi: 10.1136/ard.2005.046938. PubMed PMID: 16905582; PubMed Central PMCID: PMCPMC1798302.

64. Asano Y, Jinnin M, Kawaguchi Y, Kuwana M, Goto D, Sato S, et al. Diagnostic criteria, severity classification and guidelines of systemic sclerosis. J Dermatol. 2018;45(6):633-91. Epub 2018/04/23. doi: 10.1111/1346-8138.14162. PubMed PMID: 29687465.